Seaport Therapeutics doses first patient in GlyphAgo anxiety trial
Tweet Send to a Friend
Seaport Therapeutics (Nasdaq: SPTX) announced that the first patient has been dosed in a Phase 2a clinical trial in Australia ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




